Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Synthetic lethality and collateral lethality are two well-validated conceptual strategies for
identifying therapeutic targets in cancers with tumour-suppressor gene deletions,,. Here, we …

Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new
perspective in light of the recent advances in research. Although classical NEPC is rarely …

Context Although a number of studies have demonstrated the importance of constitutively
active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …

Prostate cancer (PCa) is a heterogeneous disease and ranked as the second leading cause
of cancer-related deaths in males worldwide. The global burden of PCa keeps rising …

Simple Summary Androgen receptor splice variant 7 (AR-V7) has always been considered a
key driver for triggering enzalutamide resistance of castration-resistant prostate cancer …

Abstract Prostate Cancer (PCa) is the second leading cause of cancer-related death in men.
Adenocarcinoma of the prostate is primarily composed of Androgen Receptor-positive (AR+) …

Prostate cancer is a highly prevalent form of cancer that is usually slow-developing and
benign. Due to its high prevalence, it is, however, still the second most common cause of …